Dyslipidemia in diabetes mellitus

被引:47
|
作者
Yoshino, G
Hirano, T
Kazumi, T
机构
[1] SHOWA UNIV, SCH MED, DEPT INTERNAL MED 1, SHINAGAWA KU, TOKYO 142, JAPAN
[2] HYOGO MED CTR ADULTS, DEPT MED, DIV ENDOCRINOL & METAB, AKASHI, HYOGO 673, JAPAN
关键词
dyslipidemia; cholesterol; triglyceride; VLDL; IDL; LDL; HDL Lp(a); postprandial lipemia;
D O I
10.1016/0168-8227(96)01263-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with diabetes mellitus have a higher rate of mortality than the general population. This higher mortality may be attributed mainly to cardiovascular disease. A high prevalence of dyslipidemia in diabetics can be one of the reasons for this. The most commonly recognized lipid abnormality in non-insulin-dependent diabetics (NIDDM) is hypertriglyceridemia, which is known to be an independent risk factor for coronary heart disease in diabetics. Hypertriglyceridemia can be produced by two mechanisms, increased synthesis of very-low-density lipoprotein (VLDL) triglyceride and removal defect of plasma triglyceride. It has been a matter of debate whether insulin always stimulates hepatic VLDL secretion but it is generally accepted that insulin deficiency results in an impairment of plasma triglyceride clearance. Considerable attention has recently been focused on the atherogenecity of postprandial hyperlipidemia, remnant lipoproteins, small, dense LDL, lipoprotein (a) [Lp(a)] and isolated hypo-alphalipoproteinemia in NIDDM subjects. Several reports suggested that these atherogenic lipoprotein abnormalities are present in NIDDMs even if they are apparently normolipidemic. Association of visceral fat obesity, insulin resistance and nephropathy may aggravate the atherogenic lipoprotein profile. Therefore, we propose here that plasma lipid levels of diabetic subjects must be more strictly controlled than for the non-diabetic population in order to avoid an increased risk for coronary heart disease. If they are obese or associated with insulin resistance or nephropathy, these conditions should be carefully controlled.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 50 条
  • [1] Treatment of dyslipidemia in patients with diabetes mellitus
    Pikto-Pietkiewicz, W
    Wolkowska, K
    Pasierski, T
    PHARMACOLOGICAL REPORTS, 2005, 57 : 10 - 19
  • [2] Dyslipidemia in type 2 diabetes mellitus
    Gadi R.
    Samaha F.F.
    Current Diabetes Reports, 2007, 7 (3) : 228 - 234
  • [3] Dyslipidemia in diabetes mellitus type 1
    Debbabi, W.
    Khochtali, I.
    Baba, A.
    Marmouche, H.
    Bchir, H.
    Mahjoub, S.
    DIABETES & METABOLISM, 2011, 37 : A75 - A75
  • [4] Dyslipidemia in type 2 diabetes mellitus
    Arshag D Mooradian
    Nature Reviews Endocrinology, 2009, 5 : 150 - 159
  • [5] Dyslipidemia And Nephropathy In Diabetes Mellitus: A Review
    Aggarwal, Juhi
    Chaudhari, Uma Kant
    Batra, Jyoti
    Sharma, Sandeep Ku-Mar
    CARDIOMETRY, 2022, (25): : 1192 - 1196
  • [6] Dyslipidemia in type 2 diabetes mellitus
    Mooradian, Arshag D.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2009, 5 (03): : 150 - 159
  • [7] The treatment of hypertension and dyslipidemia in diabetes mellitus
    Fineberg, SE
    PRIMARY CARE, 1999, 26 (04): : 951 - +
  • [8] Dyslipidemia in youth with type 2 diabetes mellitus
    Yung, GS
    Dean, HJ
    Sellers, EAC
    PEDIATRIC RESEARCH, 2003, 53 (04) : 140A - 140A
  • [9] Dyslipidemia as a atherogenic risk factor in diabetes mellitus
    Hancu, N
    Cerghizan, A
    Iancu, S
    Duma, L
    Marian, A
    Cota, A
    ATHEROSCLEROSIS, 1999, 144 : 125 - 125
  • [10] Recent dyslipidemia guidelines for patients with diabetes mellitus
    Rhee, Eun-Jung
    PRECISION AND FUTURE MEDICINE, 2020, 4 (04): : 133 - 140